Last reviewed · How we verify

NCT04882384

Pericapsular Nerve Group Block for Hip Fractures

Completed NA Last updated 21 March 2022
What this trial tests

NA trial testing Pericapsular Nerve Group Block in Hip Fractures in 10 participants. Completed in 15 March 2022.

Timeline
1 July 2021
Primary endpoint
15 March 2022
15 March 2022

Quick facts

Lead sponsorJacobi Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment10
Start date1 July 2021
Primary completion15 March 2022
Estimated completion15 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Jacobi Medical Center

Who can join

18 and older, any sex, with Hip Fractures or Pain, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a feasibility study to see if it feasible to perform the Pericapsular Nerve Group Block for hip fractures in the Emergency Department. In addition, we will look at the efficacy of the block in these 10 patients by measuring pain scores at pre-determine time points for 16 hours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pericapsular Nerve Group Block

Trials testing the same drug.

Other recruiting trials for Hip Fractures

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04882384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing